drugset / Trial / NCT01158599

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

NCT01158599

Phase 4 Completed 200 enrolled Valneva Austria GmbH
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This is an open-label, uncontrolled phase 4 study to assess the safety and immunogenicity of the Japanese encephalitis (JE) vaccine Ixiaro® (IC51) in an elderly population.

Timeline

Start
2010-06
Primary completion
2011-06
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject IC51 Vaccine 6 ug Intramuscular
Subject IC51 Vaccine 0.5 ml Intramuscular

Indications